Clever Culture Systems (CC5: $0.032) has announced the sale of its APAS Independence instrument to its fourth major customer, Novo Nordisk, the supplier of the weight-loss drug Ozempic. The APAS instrument costs around US $350,000, with the potential for Novo Nordisk to deploy it across its 16 major production facilities (potential sales of US $8.6 million). Novo Nordisk has purchased the instrument to assess its functionality by its centralized team in Denmark. If it performs well, a rollout across all major manufacturing sites can be expected.